Hematopoiesis News 11.09 March 10, 2020 | |
| |
TOP STORYNotch Ligand Dll4 Impairs Cell Recruitment to Aortic Clusters and Limits Blood Stem Cell Generation Investigators used advanced live imaging techniques of organotypic slice cultures, clonal analysis, and mathematical modeling to show the two‐step process of intra‐aortic hematopoietic cluster formation. [EMBO J] Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers generated iPSCs from healthy donor peripheral blood mononuclear cells and analyzed the proliferation and differentiation capacities of the generated iPSCs using single cell NGS-based 24-chromosome aneuploidy screening and RNA sequencing. [J Clin Med] Full Article The authors demonstrated that ubiquitin‐specific protease 7 (USP7) expression was elevated in myelodysplastic syndrome (MDS) cell lines and patient samples. The USP7‐selective small‐molecule inhibitors P5091 and P22077 inhibited cell proliferation and induced megakaryocytic differentiation in both cell lines and primary cells. [Br J Haematol] Abstract To identify new effectors of mesenchymal migration, scientists produced ER-Hoxb8-immortalized hematopoietic progenitors, which showed unlimited proliferative ability in the presence of estrogen. [J Cell Sci] Abstract Investigators studied a cohort of 367 healthy related donors who volunteered to donate their hematopoietic stem cells for allogeneic transplantation. They searched whether inter-individual variations in known genetic polymorphisms located in genes whose products were functionally important for mobilization, and could affect the extent of CD34+ mobilization, either individually or in combination. [PLoS One] Full Article Researchers used a patented in vitro aging model of hematopoietic stem/progenitor cells (HSPCs) to analyze mRNA splicing relevant protein alterations with iTRAQ-based proteomic analysis. They found that not only the notable mRNA splicing genes such as SR, hnRNP, WBP11, Sf3b1, Ptbp1 and U2AF1 but also the scarcely reported mRNA splicing relevant genes such as Rbmxl1, Dhx16, Pcbp2, Pabpc1 were significantly down-regulated. [Aging Clin Exp Res] Abstract CLINICAL RESEARCHScientists studied factors that could help identify patients at a higher risk of relapse or death. This retrospective study included 79 patients who underwent first hematopoietic cell transplantation for myelofibrosis at three centers between 2005 and 2016. [Blood Cancer J] Abstract Researchers report the results of an analysis of unrelated allogeneic hematopoietic stem cell transplantations in 71 patients with sickle cell disease transplanted in EBMT centers between 2005 and 2017. [Bone Marrow Transplant] Abstract To remedy the lack of HLA matched donors and address the problems bedeviling traditional allogeneic hematopoietic stem cell transplantation which induces the resultant graft-versus-host disease, scientists designed a scheme called HLA-mismatched hematopoietic stem cell micro-transplantation for patients with acute myeloid leukemia, where encouraging results were achieved. [Stem Cells Dev] Abstract Subscribe to one of our other 19 science newsletters such as Cord Blood News & Cell Therapy News. | |
| |
REVIEWSBone Marrow Niches in Hematological Malignancies The authors summarize the current understanding of the composition and function of the specialized hematopoietic niches of the bone marrow during health and disease. [Nat Rev Cancer] Abstract Interplay between Clonal Hematopoiesis of Indeterminate Potential and Metabolism Scientists discuss the role of clonal hematopoiesis of indeterminate potential (CHIP), the interplay between CHIP and metabolic diseases, as well as how metabolism of HSCs could regulate CHIP-related HSC fate. [Trends Endocrinol Metab] Abstract Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
INDUSTRY NEWSTG Therapeutics, Inc. announced that the FDA granted orphan drug designation to umbralisib, the company’s investigational dual inhibitor of PI3K-delta and CK1-epsilon, for the treatment of patients with follicular lymphoma. [TG Therapeutics, Inc.] Press Release Bristol Myers Squibb Company announced topline results from ELOQUENT-1, a Phase III, randomized, open-label trial evaluating the combination of Empliciti plus Revlimid and dexamethasone, versus Revlimid and dexamethasone alone, in patients with newly diagnosed, previously untreated multiple myeloma who are transplant ineligible. [Bristol Myers Squibb Company] Press Release AVROBIO Receives Orphan Drug Designation from US FDA for AVR-RD-04 for Cystinosis AVROBIO, Inc. announced that the FDA has granted orphan drug designation to the company’s investigational gene therapy, AVR-RD-04, for the treatment of cystinosis. [AVROBIO, Inc.] Press Release Ascentage Pharma announced that two clinical studies of APG-2575, a novel Bcl-2 selective inhibitor being developed by Ascentage Pharma, have recently received clearances from the FDA. [Ascentage Pharma (PR Newswire Association, LLC.)] Press Release | |
| |
POLICY NEWSNearly two years ago, Charles River Laboratories paid $800 million for a company called MPI Research to bolster its business running clinical trials for drug makers and other companies. But Charles River did not know one MPI employee was an also undercover agent for the Humane Society of the United States and secretly filmed experiments conducted on various dogs, which were later publicized on the internet. [STAT News] Editorial New Trump Rules Aim to Fuel Sharing of Patient Health Records by Smartphone President Trump’s top health care aides said they will finalize federal rules requiring health providers and insurers to make health records available to patients in an easily accessible electronic format, a policy shift aimed at fueling broader efforts to use patient data to develop new software tools and services. [STAT News] Editorial
| |
EVENTSNEW Diverse Organisms and Common Mechanisms in Cell-Cell Fusion Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Hematopoiesis Research (Harvard Medical School) Postdoctoral Researcher – Pediatric Oncology (Universitätsklinikum Carl Gustav Carus) Research Associate – Stem Cell and Gene Therapy Program (Fred Hutchinson Cancer Research Center) Postdoctoral Position – RNA Modifications, Hematopoiesis and Cancer (Lund University) Postdoctoral Fellow Positions – Hematopoietic Stem Cell Biology (Nationwide Children’s Hospital) Postdoctoral Researcher – Bioinformatics and Leukemia Stem Cells (The Centre for Genomic Regulation) Postdoctoral Fellow – Hereditary and Childhood Tumors (The University of British Columbia) Postdoctoral Fellowship – Personalized Cancer Treatments (MGH Cancer Center) Assistant/Associate Professor – Hematology & Oncology (UC Davis School of Medicine) Associate/Professor – Hematology & Oncology (UC Davis School of Medicine) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|